CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3 enrolled
Drug / intervention
nVNS +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04935697
NCT04935697N/ACompleted

Non-invasive Vagal Neurostimulation (nVNS) to Mitigate Traumatic Brain Injury (TBI)-Induced Acute Respiratory Distress and Acute Lung Injury

In Brief

A clinical study evaluating nVNS and SOC for Acute Respiratory Distress Syndrome and 3 related conditions. Completed, enrolled 3 participants across 1 site.

Detailed Summary

This is a prospective, randomized, two-arm, controlled 30-day investigational pilot trial using the gammaCore Sapphire S non-invasive vagus nerve stimulation (nVNS) device + standard of care (SOC) in newly-hospitalized patients with mild-to-moderate traumatic brain injury (TBI) to prevent the progression towards immunokine storms, systemic inflammatory response syndrome (SIRS), severe respiratory distress, and requirement for invasive mechanical ventilation, and death, when compared to SOC alone (the control arm).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJun 23, 2021
Enrollment StartAug 4, 2021
Primary CompletionMar 1, 2025
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 5.0 years ago

Interventions

nVNSdevice

3x daily treatment of nVNS + SOC

SOCother

Standard of care patient management.